Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral Eubacterium hallii for postprandial glucose control in metformin-treated men with type 2 diabetes
NL-OMON55732Phase 2Active, not recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Nov 2018
- Countries
- 1
01
Overview
Phase 2 trial in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Amsterdam University Medical Center. Primary endpoint: Postprandial glucose excursions by continuous glucose monitoring. Started Nov 2018; status: active, not recruiting.
02
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NL-OMON55732.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55732.